Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTION
• To assess the efficacy of anidulafungin and caspofungin with respect to the overall global response (clinical and microbiological success) at the EOT in subjects with a confirmed diagnosis of deep t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer (Canada)
Update Il y a 4 ans
Effect of pregabalin in acute post-operative pain and functional recovery for laparoscopic cholecystectomy
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc. 235 East 42nd street – New York – 10017 NY - USA
Update Il y a 4 ans
A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER
To demonstrate that the combination of sunitinib plus capecitabine is superior to capecitabine monotherapy in prolonging the progression-free survival (PFS) for ABC patients
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Ltd
Update Il y a 4 ans
Double-blind, parallel-group, randomized, study of the efficacy and safety of continuous use of celecoxib vs the “usual use” of celecoxib in the treatment of subjects with chronicosteoarthritis of the hip or knee who require an anti-inflammatory medication for control of their pain
To determine whether continuous use over a 6-month period of celecoxib 200 mg per day is more effective than intermittent use of celecoxib 200 mg per day in preventing spontaneous OA flares.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A study to measure pretection (antibody response) and safety against representative strains causing a high proportion of disease (Meningococcal Group B) in healthy subject aged between 12 and <19 years
Primary Immunogenicity Objective • To describe the immune response, relative to baseline status, following receipt of Bexsero as measured by hSBA performed with a panel of MnB test strains assessed ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Update Il y a 4 ans
A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)
The primary objective of this trial is to evaluate the efficacy of Genotropin® treatment on height velocity SDS in short SGA children starting treatment at an age of 24-30 months as compared to untrea...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Ltd
Update Il y a 4 ans
A randomised, double-blind, parallel group trial to assess the variability and treatment effect size for a Neuropathic Pain offset design
To estimate the difference in average daily pain score (ADPS) after 4 weeks in patients maintained on the ‘standard’ dose of gabapentin compared to those on a reduced dose of gabapentin. To estimate t...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Update Il y a 4 ans
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF CP-945,598 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS
To evaluate the efficacy of 20 mg QD and 5 mg QD of CP-945,598 given for 48 weeks in the treatment of NASH.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
A 15-WEEK CLINICAL STUDY TO DETERMINE THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF PF-06649751 IN PATIENTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE UN ESTUDIO CLÍNICO DE 15 SEMANAS PARA DETERMINAR LA EFECTIVIDAD, SEGURIDAD Y TOLERABILIDAD DE PF-06649751 EN PACIENTES CON FLUCTUACIONES MOTORAS POR ENFERMEDAD DE PARKINSON
- To evaluate the effect on motor symptoms of PF-06649751 administered once daily as adjunctive treatment with stable doses of L-Dopa in Parkinson's disease. - To determine the therapeutic window for ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Ltd
Update Il y a 4 ans
A double-blind (third party open), placebo-controlled, parallel group, multiple dose study to investigate the safety, toleration and pharmacokinetics of [S,S]-Reboxetine in young and elderly healthy volunteers
To investigate the safety and toleration of multiple oral doses of (+)-[S,S]-RBX administeredonce daily in an extended release formulation in young and elderly volunteers. To investigate the steady ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
13
14
15
16
17
18
19
20
21
22
Next